# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
HC Wainwright & Co. analyst Ed Arce reiterates Pliant Therapeutics (NASDAQ:PLRX) with a Buy and maintains $36 price target.
Pliant Therapeutics, Inc. (NASDAQ:PLRX), a late-stage biotechnology company and leader in the discovery and development of nove...
In an oral presentation, Gregory P. Cosgrove, M.D., FCCP, Vice President of Clinical Development at Pliant Therapeutics provide...
HC Wainwright & Co. analyst Ed Arce reiterates Pliant Therapeutics (NASDAQ:PLRX) with a Buy and maintains $36 price target.
Phase 2a trial results of Pliant Therapeutics' bexotegrast (PLN-74809) for idiopathic pulmonary fibrosis. Reduced lung coll...
Citigroup analyst David Lebowitz maintains Pliant Therapeutics (NASDAQ:PLRX) with a Buy and lowers the price target from $45...
RBC Capital analyst Brian Abrahams maintains Pliant Therapeutics (NASDAQ:PLRX) with a Outperform and lowers the price target...